Study guide

3.2 Electrolyte Disorders in the ICU

Board Certified Critical Care Pharmacist Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pathophysiology and Recognition of Critical Illness

1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness

2 Chapter 2: Medical Devices and Circulatory Support

2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care

3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management

3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation

4 Chapter 4: Vasoactive and Inotropic Therapy in Shock

4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock

5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)

5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness

6 Chapter 6: Cardiovascular Emergencies

6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias

7 Chapter 7: Pulmonary and Infectious Diseases in the ICU

7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU

8 Chapter 8: Neurocritical Care

8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury

9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies

9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy

10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition

10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral

11 Chapter 11: Quality, Safety, and Clinical Guidelines

11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions

12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine

12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management

13 Chapter 13: Treatment Planning and Care Coordination

13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education

3.2 Electrolyte Disorders in the ICU

Key Takeaways Explain This Topic AI

Severe, symptomatic hyponatremia (e.g., seizures, coma) is a medical emergency requiring rapid but limited correction with 3% hypertonic saline to reverse cerebral edema.

To prevent osmotic demyelination syndrome (ODS), the rate of sodium correction in chronic hyponatremia should not exceed 8 mEq/L per 24 hours.

Hyperkalemia management requires a step-wise approach: membrane stabilization (calcium), intracellular shifting (insulin/dextrose, albuterol, bicarbonate), and elimination (loop diuretics, binders, dialysis).

Hypokalemia and hypocalcemia are often refractory to treatment if concomitant hypomagnesemia is not corrected first, as magnesium acts as a cofactor for key cellular ion channels.

Last updated: July 2026

Electrolyte Disorders in the ICU

Electrolyte abnormalities are ubiquitous in the intensive care unit, arising from underlying disease processes, organ dysfunction, and iatrogenic interventions (e.g., medications, fluid therapy). Prompt recognition and appropriate management of these disorders are critical, as severe derangements can lead to life-threatening arrhythmias, neurologic catastrophes, and death. The BCCCP must expertly navigate the complexities of replacing, shifting, or removing electrolytes.

Sodium Disorders: Hyponatremia

Hyponatremia (serum sodium < 135 mEq/L) is primarily a disorder of water balance, not necessarily a sodium deficit. It is the most common electrolyte abnormality in hospitalized patients. The diagnostic approach begins with assessing serum osmolality to confirm true (hypotonic) hyponatremia, followed by an assessment of the patient's volume status (hypovolemic, euvolemic, or hypervolemic).

Management of Severe Symptomatic Hyponatremia

When a patient presents with severe hyponatremia (typically < 120 mEq/L) accompanied by severe neurologic symptoms (seizures, coma, severe altered mental status), this represents acute cerebral edema and constitutes a medical emergency. The treatment of choice is 3% hypertonic saline .

Goal: The immediate goal is to rapidly increase the serum sodium by 4 to 6 mEq/L over the first few hours. This small increase is usually sufficient to reverse life-threatening cerebral edema and arrest seizures.

Dosing: A common approach is to administer 3% saline as a 100-150 mL bolus over 10-20 minutes, which can be repeated up to two times if severe symptoms persist.

The Risk of Overcorrection: While rapid initial correction is necessary for acute symptoms, correcting sodium too quickly overall poses a severe risk of Osmotic Demyelination Syndrome (ODS) (formerly central pontine myelinolysis). ODS causes irreversible neurologic damage (paralysis, dysphagia, "locked-in" syndrome). To prevent ODS, the total correction of serum sodium must not exceed 8 mEq/L in any 24-hour period (and no more than 18 mEq/L in 48 hours) for patients with chronic hyponatremia or hyponatremia of unknown duration.

Potassium Disorders

Potassium is the primary intracellular cation. Even small changes in the extracellular potassium concentration can have profound effects on the resting membrane potential of cardiac and neuromuscular cells.

Hyperkalemia

Hyperkalemia (serum potassium > 5.0 mEq/L) is common in the ICU, often resulting from acute kidney injury (AKI), medications (ACE inhibitors, ARBs, potassium-sparing diuretics), rhabdomyolysis, or metabolic acidosis (which causes extracellular potassium shift). Severe hyperkalemia (> 6.5 mEq/L) or hyperkalemia with EKG changes (peaked T waves, widened QRS, loss of P wave, sine wave) requires immediate intervention using a three-pronged approach:

Membrane Stabilization:

Agent: Intravenous Calcium (Calcium Gluconate or Calcium Chloride).

Mechanism: Calcium antagonizes the membrane actions of hyperkalemia, raising the threshold potential and stabilizing the myocardium, thereby preventing lethal arrhythmias. It does not lower the serum potassium level.

Note: Calcium chloride provides three times more elemental calcium per 10 mL ampule than calcium gluconate but requires central venous access due to the risk of severe tissue necrosis with extravasation. Calcium gluconate is preferred for peripheral administration.

Intracellular Shifting:

Agents: Regular Insulin (with Dextrose to prevent hypoglycemia), Albuterol (high-dose nebulized), Sodium Bicarbonate (primarily effective if concurrent metabolic acidosis is present).

Mechanism: These agents drive potassium from the extracellular space into the intracellular space. The effect is rapid (onset 15-30 mins) but temporary (duration 2-6 hours).

Elimination:

Agents: Loop diuretics (e.g., furosemide, if the patient makes urine), Gastrointestinal cation-exchange resins/binders (e.g., sodium polystyrene sulfonate, patiromer, sodium zirconium cyclosilicate), or Hemodialysis.

Mechanism: These are the only methods that actually remove potassium from the body. Hemodialysis is the most rapid and effective method, indicated for severe, refractory hyperkalemia or when significant AKI/anuria is present.

Hypokalemia

Hypokalemia (serum potassium < 3.5 mEq/L) can cause muscle weakness, respiratory failure, and dangerous arrhythmias (e.g., Torsades de Pointes). Treatment involves oral or intravenous potassium replacement. A critical concept in managing hypokalemia is the role of magnesium.

Magnesium Disorders

Magnesium is the second most abundant intracellular cation and acts as a crucial cofactor in over 300 enzymatic reactions, including those involving ATP and the Na+/K+ ATPase pump.

Hypomagnesemia and Refractory Hypokalemia

Hypomagnesemia (serum magnesium < 1.5 mg/dL) frequently coexists with hypokalemia. Importantly, hypokalemia is often refractory to potassium replacement if concurrent hypomagnesemia is not corrected first.

Mechanism: Magnesium is required for the proper function of the Na+/K+ ATPase pump, which maintains intracellular potassium. Furthermore, low intracellular magnesium in the distal renal tubule removes the inhibitory check on the ROMK (Renal Outer Medullary Potassium) channel, leading to excessive renal potassium wasting. Until magnesium is repleted, administered potassium will continue to be lost in the urine.

Management: Always check a magnesium level in patients with hypokalemia. Intravenous magnesium sulfate (typically 1-4 grams depending on severity) is the treatment of choice for significant hypomagnesemia in the ICU.

Clinical Scenario

A 58-year-old female with chronic kidney disease (baseline creatinine 1.8 mg/dL) is admitted to the ICU with profound weakness. Her medications include lisinopril and spironolactone. Her lab results reveal a serum potassium of 7.2 mEq/L and a creatinine of 3.4 mg/dL. Her EKG shows significantly widened QRS complexes and peaked T waves.

This patient has life-threatening hyperkalemia with EKG changes. The immediate priority is myocardial stabilization to prevent ventricular fibrillation. She should immediately receive IV calcium (gluconate peripherally or chloride centrally). Following calcium, she requires therapies to shift potassium intracellularly (10 units of IV regular insulin administered with 50 mL of 50% dextrose). Finally, because she has acute kidney injury on top of chronic kidney disease and is likely oliguric, she will likely require urgent hemodialysis to definitively remove potassium from her body, though loop diuretics and GI binders can be attempted if dialysis is delayed.